Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S279000
Reexamination Certificate
active
06878716
ABSTRACT:
This invention pertains to compounds which specifically inhibit the adenosine A1receptor and the use of these compounds to treat a disease associated with A1adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
REFERENCES:
patent: 3037980 (1962-06-01), Hitchings et al.
patent: 3910913 (1975-10-01), Kim et al.
patent: 5296484 (1994-03-01), Coghlan et al.
patent: 5409930 (1995-04-01), Spada et al.
patent: 5516894 (1996-05-01), Reppert
patent: 5580870 (1996-12-01), Barker et al.
patent: 5639913 (1997-06-01), Lidor et al.
patent: 5646130 (1997-07-01), Shi
patent: 5646156 (1997-07-01), Jacobson et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5714493 (1998-02-01), Myers et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5780450 (1998-07-01), Shade
patent: 5780481 (1998-07-01), Jacobson et al.
patent: 5834609 (1998-11-01), Horne et al.
patent: 5877218 (1999-03-01), Herzig et al.
patent: 5877221 (1999-03-01), Cohen et al.
patent: 5880159 (1999-03-01), Herzig et al.
patent: 5914349 (1999-06-01), Cohen et al.
patent: 5962458 (1999-10-01), Lohmann et al.
patent: 5994408 (1999-11-01), Cohen et al.
patent: 6680322 (2004-01-01), Castelhano et al.
patent: 6680324 (2004-01-01), Castelhano et al.
patent: 6686366 (2004-02-01), Castelhano et al.
patent: 20020028782 (2002-03-01), Castelhano et al.
patent: 20020058667 (2002-05-01), Castelhano et al.
patent: 20020094974 (2002-07-01), Castelhano et al.
patent: 20030036545 (2003-02-01), Castelhano et al.
patent: 20030045536 (2003-03-01), Castelhano et al.
patent: 20030073708 (2003-04-01), Castelhano et al.
patent: 3145287 (1983-05-01), None
patent: 0322242 (1989-06-01), None
patent: 0514540 (1992-11-01), None
patent: 0682027 (1995-11-01), None
patent: 0729758 (1996-09-01), None
patent: 0773023 (1997-05-01), None
patent: 915303 (1963-01-01), None
patent: 157280 (1986-02-01), None
patent: 9291089 (1999-05-01), None
patent: WO9320078 (1993-10-01), None
patent: WO9413676 (1994-06-01), None
patent: WO9417090 (1994-08-01), None
patent: WO9424136 (1994-10-01), None
patent: WO9511681 (1995-05-01), None
patent: WO9518617 (1995-07-01), None
patent: WO9519774 (1995-07-01), None
patent: WO9519970 (1995-07-01), None
patent: WO9520597 (1995-08-01), None
patent: WO9619478 (1996-06-01), None
patent: WO9702266 (1997-01-01), None
patent: WO9705138 (1997-02-01), None
patent: WO9733879 (1997-09-01), None
patent: WO9807726 (1998-02-01), None
patent: WO9808382 (1998-03-01), None
patent: WO9822465 (1998-05-01), None
patent: WO9829397 (1998-07-01), None
patent: WO9857651 (1998-12-01), None
patent: WO9906053 (1999-02-01), None
patent: WO9908460 (1999-02-01), None
patent: WO9933815 (1999-07-01), None
patent: WO9942093 (1999-08-01), None
patent: WO9962518 (1999-12-01), None
patent: WO0003741 (2000-01-01), None
Nyce J. W. and Metzger J.W., (1997) “DNA antisense therapy for asthma in an animal model”,Nature, 385: 721-725 (Exhibit 43).
Pichler, H. et al. (1986) “Synthese of 7-unsubstituierten 7H-Pyrrolo[2,3-d] pyrimidines”,Liebigs Ann. Chemie., 9: 1485-1505 (Exhibit 44).
Seela, F., and Lupke, U., (1977)U. Chem. Ber., 110:1462-1469 (Exhibit 45).
Strohmeier, G. R. et al., (1995) “The A2bAdenosine Receptor Mediates cAMP Responses to Adenosine Receptor Agonists in Human Intestinal Epithelia”,J. Bio. Chem., 270: 2387-2394 (Exhibit 46).
Williams, E. F. et al., (1994) “Nucleoside transport sites in a cultured human retinal cell line established by SV-40 T antigen gene”,Current Eve Research, 13: 109-118 (Exhibit 47).
Woods, C. L. and Blazynski, C. (1991) “Characterization of Adenosine A1-receptor Binding Sites in Bovine Retinal Membranes”,Experimental Eve Research, 53: 325-331 (Exhibit 48).
Abbracchio M., et al., (1999) “Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative Diseases”,Ann. NY. Acad. Sci, 890: 79-92 (Exhibit 5).
Abbracchio M., et al., (1997) “Modulation of Apoptosis by Nervous System: a Possible Role for the A3Receptor”,Ann. NY. Acad. Sci., 825: 11-22 (Exhibit 6).
Baraldi P., et al., (2000) “New potent and selective human adenosine A3receptor antagonists”,Tips, 21: 456-459 (Exhibit 7).
Brand A., et al., (2001) “Adenosine A1 and A3 receptors mediate inhibition of synaptic transmission in rat cortical neurons”,Neuropharmacology, 40: 85-95 (Exhibit 8).
Casavola V., et al., (1998) “Adenosine A3 receptor activation increases cystolic calcium concentration via calcium influx in A6 cells”,Drug Development Research, 43 (1): 62 (Exhibit 9).
Ezeamuzie C., et al., (1999) “Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release”,British Journal of Pharmacology, 127: 188-194 (Exhibit 10).
Fozard J., et al., (1996) “Mast cell degranulation following adenosine A3 receptor activation in rats”,European Journal of Pharmacology, 298: 293-297 (Exhibit 11).
Franco M., et al., (1999) “Adenosine Regulates Renal Nitric Oxide Production in Hypothyroid Rats”,Journal of the American Society of Nephrology, 1681-1688 (Exhibit 12).
Guerra L., et al., (1998) “Adenosine A3 receptor activation increases cytosolic calcium influx in A6 cells”,Nephrology Dialysis Transplantation, 13 (6): A5 (Exhibit 13).
Jacobson K.A., et al., (1998) “Adenosine A3 receptors: novel ligands and paradoxical effects”,Tips, 19:184-191 (Exhibit 14).
Jacobson K.A., et al., (1997) “Pharmacological Characterization of Novel A3 Adenosine Receptor-selective Antogonists”,Neuropharmacology, 36 (9): 1157-1165 (Exhibit 15).
Lee T., et al., (2000) “Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors”,Am. J. Physiol. Renal Physiol., 278: F380-F387 (Exhibit 16).
Ohana G., et al., (2001) “Differential Effect of Adenosine on Tumor and Normal Cell Growth: Focus on the A3 Adenosine Receptor”,Journal of Cellular Physiology, 186: 19-23 (Exhibit 17).
Regulation of Downstream Effectors By GFCRs, (1999)FASEB J., Abstracts 147.1-147.6 (Exhibit 18).
Reshkin J., et al., (2000) “Activation of A3 Adenosine Receptor Induces Calcium Entry and Chloride Secretion in A6 Cells”,J. Membrane Biol., 178: 103-113 (Exhibit 19).
Sawynok J., et al., (1997) “Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine”,European Journal of Pharmacology, 333: 1-7 (Exhibit 20).
Von Lubitz, D., et al., (1999) “Chronic administration of adenosine A3 receptor agonist and cerebral eschemia: neuronal and glial effects”,European Journal of Pharmacology, 367: 157-163 (Exhibit 21).
Von Lubitz D., et al., (1999) “Stimulation of Adenosine A3 Receptors in Cerebral Ischemia”,Ann. NY. Acad. Sci., 890: 93-106 (Exhibit 22).
Yao Y., et al., (1997) “Adenosine A3 Receptor Agonists Protect HL-60 and U-937 Cells from Apoptosis Induced by A3 Antagonists”,Biochemical And Biophysical Research Communications, 232: 317-322 (Exhibit 23); and.
Zhao Z., et al., (2000) “A role for the A3 Adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice”,Biochimica et Biophysica Acta, 1500: 280-290 (Exhibit 24).
Lee T., et al., (1999) “Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors”,72ndScientific Sessions of the American Heart Association, Atlanta, GA, p. 197 (Exhibit 26).
DeNinno, M.P. inAnnual Reports in Medicinal Chemistry, vol. 33, (Academic Press: San Diego, 1998), pp. 111-120 (Exhibit 27).
Hart, H. et al.,Organic Chemistry, A Short Course, (Houghton Mifflin: 1995), p. 121 (Exhibit 28).
Mautner, H.G. (1961) “Potential Deoxyribonucleic Acid Cross-linking Agents. 8,8′-Bisp
Castelhano Arlindo L.
McKibben Bryan
Witter David J.
Cooper & Dunham LLP
OSI Pharmaceuticals, Inc.
Raymond Richard L.
White John P.
LandOfFree
Compounds specific to adenosine A1 receptor and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds specific to adenosine A1 receptor and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds specific to adenosine A1 receptor and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3436834